Vyome Holdings, Inc. HIND
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -47.67%
- 1 year
- -67.74%
- Open
- 1.73
- Prev close
- 1.73
- Mkt cap
- 12.63M
- Vol
- 42.19K
- Avg vol
- 12.73K
- EPS
- 1.78
- P/E
- 1.01
- Div yield
- 0.00%
More statistics
- Low
- 1.72
- High
- 2.14
News
6 days ago businesswire.com
Vyome Co-Founder Dr. Shiladitya Sengupta Promoted to Professor at Harvard Medical School
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Holdings, Inc. (Nasdaq: HIND) ("Vyome"), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions,…
3 weeks ago businesswire.com
Vyome Receives USPTO Notice of Allowance for U.S. Patent Covering VT-1908, its Novel Topical Mycophenolate Program Targeting the $20+ Billion Ocular Inflammation Market
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND #ocularinflammation--Vyome Holdings, Inc. (Nasdaq: HIND) (“Vyome”), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare…
-
1 month ago benzinga.com
Vyome Holdings' ReShape Lifesciences Has Received A Notice Of Allowance For A U.S. Patent Titled "VAGUS NERVE NEUROMODULATION FOR THE TREATMENT OF THE HYPOGLYCEMIC STATE".
https://patentcenter.uspto.gov/applications/18702356/ifw/docs
-
1 month ago benzinga.com
Vyome Holdings Appoints Jerry Leonard As CFO, Succeeding Robert Dickey IV, Who Served As Interim CFO Since August 2025
Finance executive with more than 25 years of experience brings extensive expertise in public company financial management, SEC reporting, financial operations, and governanceVyome Holdings, Inc.…
1 month ago businesswire.com
Vyome Appoints Experienced Public Company Finance Executive Jerry Leonard as Chief Financial Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND #CFO--Vyome Holdings, Inc. (Nasdaq: HIND) (“Vyome” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated…
-
1 month ago benzinga.com
Chardan Capital Initiates Coverage On Vyome Holdings with Buy Rating, Announces Price Target of $3.5
Chardan Capital analyst Keay Nakae initiates coverage on Vyome Holdings (NASDAQ:HIND) with a Buy rating and announces Price Target of $3.5.
-
2 months ago benzinga.com
Vyome Appoints Jerry Leonard As CFO On August 27, 2026
On August 27, 2026, the board of directors (the "Board") of Vyome Holdings, Inc. (the "Company") appointed Jerry Leonard as the Company’s Chief Financial Officer. In connection with Mr. Leonard’s
2 months ago businesswire.com
Vyome Holdings Reports Second Quarter 2026 Results Highlighted by Advancement of Lead VT-1953 Program, Pipeline Expansion and Strong Balance Sheet
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Holdings, Inc. (Nasdaq: HIND, “Vyome”), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, today…
2 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers AbCellera Biologics (NASDAQ:ABCL) shares increased by 8.2% to $7.5 during Friday's after-market session. The company's market cap stands at $1.9 billion. As per the news, the Q2 earnings…
-
4 months ago benzinga.com
China National Intellectual Property Administration Grants Vyome Patent Chinese Patent No. ZL 2021 1 0758695.X
Newly granted Chinese patent broadens Vyome's intellectual property estate with additional formulation and therapeutic use claims for besifloxacin gel in inflammatory acne, supporting future…
4 months ago businesswire.com
Vyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND #VT1953--Vyome Holdings, Inc. (NASDAQ: HIND) (“Vyome” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated…
5 months ago gurufocus.com
Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet
Vyome Holdings, Inc. (Nasdaq: HIND)(âVyomeâ), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, today
5 months ago businesswire.com
Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings, Inc. (Nasdaq: HIND)(“Vyome”), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, today reports…
5 months ago businesswire.com
Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings, Inc. (“Vyome”) (Nasdaq: HIND) today announced the signing of an agreement with Impetis Biosciences Limited (“Impetis”), a TATA Enterprise, that…
-
6 months ago benzinga.com
Vyome Holdings Reports Data On Its Phase 2 Investigator Initiated Trial Results, Preclinical Data Of VT-1953 To Treat Symptoms Of Malignant Fungating Wounds At American Association For Cancer Research Annual Meeting
Vyome Holdings, Inc. ("Vyome") (Nasdaq: HIND) presented its full Phase 2 investigator initiated study results and preclinical data supporting the efficacy and safety of VT-1953 as a potential…
6 months ago businesswire.com
Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026.
-
6 months ago benzinga.com
Vyome Holdings To Present Full Phase 2 Investigator Initiated Study Results And Preclinical Data Supporting Efficacy And Safety Of VT-1953 As Potential Treatment For Malodor And Other Symptoms Of MFW At 2026 AACR
Complete Phase 2 clinical data on the efficacy and safety of VT-1953 in MFW patients accepted for presentation at the annual meeting of the American Association for Cancer ResearchVyome Holdings,…
6 months ago businesswire.com
Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings, Inc. (“Vyome”) (Nasdaq: HIND) today announced that the company will present its full Phase 2 investigator initiated study results and preclinical…
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
7 months ago businesswire.com
Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase.
8 months ago businesswire.com
Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome announces the publication of positive preclinical results in uveitis, addressing a $3B potential market opportunity.
-
8 months ago benzinga.com
Vyome Files For Orphan Drug Status For VT-1953, Its Lead Clinical Program
Acceptance of Orphan Drug Status would confer certain anticipated US Market Exclusivity, R&D tax benefits, and PDUFA fee waiver of approximately $3MIndependent third-party assessment estimates a…
8 months ago businesswire.com
Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings, Inc. (“Vyome”) (NASDAQ: HIND), a clinical-stage biopharmaceutical company focused on developing therapies for serious immuno-inflammatory and rare…
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
9 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
9 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
9 months ago businesswire.com
Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results.
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
9 months ago benzinga.com
Vyome Shares Move Higher; Co Highlights Independent Analyst Valuation Of Vyome
Third-party analysis estimates the total addressable U.S. market to be approximately USD 2.2 billionModeled peak annual U.S. sales approaching USD 600 million for VT-1953Independent valuation…
9 months ago businesswire.com
Independent Analyst Values Vyome's VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Independent Analyst Values Vyome's VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study.
9 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
9 months ago defenseworld.net
Vyome (NASDAQ:HIND) versus Medline (NASDAQ:MDLN) Critical Review
Medline (NASDAQ: MDLN - Get Free Report) and Vyome (NASDAQ: HIND - Get Free Report) are both manufacturing companies, but which is the better business? We will contrast the two businesses based on…
10 months ago defenseworld.net
Vyome (NASDAQ:HIND) & Medline (NASDAQ:MDLN) Critical Analysis
Vyome (NASDAQ: HIND - Get Free Report) and Medline (NASDAQ: MDLN - Get Free Report) are both manufacturing companies, but which is the superior investment? We will compare the two businesses based on…
-
10 months ago benzinga.com
Vyome Holdings' Subsidiary LiveChain Enters Binding LOI To Acquire Humanyze Convertible Note In Equity Exchange with Remus Capital
Entry into a Material Definitive Agreement Letter of Intent with LICH and Remus: On December 17, 2025, Vyome Holdings, Inc. (the "Company") entered into a binding letter of intent (the "LOI") among,…
10 months ago businesswire.com
Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company
CAMBRIDGE, Mass.--(BUSINESS WIRE)--LICH LOI with Remus.
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
10 months ago defenseworld.net
Analyzing Profusa (NASDAQ:PFSA) & Vyome (NASDAQ:HIND)
Vyome (NASDAQ: HIND - Get Free Report) and Profusa (NASDAQ: PFSA - Get Free Report) are both small-cap manufacturing companies, but which is the superior stock? We will compare the two companies…
10 months ago defenseworld.net
Critical Survey: Perspective Therapeutics (NASDAQ:CATX) & Vyome (NASDAQ:HIND)
Vyome (NASDAQ: HIND - Get Free Report) and Perspective Therapeutics (NASDAQ: CATX - Get Free Report) are both small-cap manufacturing companies, but which is the superior business? We will compare…
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
10 months ago benzinga.com
Vyome's VT-1953 Announces Phase 2 Efficacy In Malignant Fungating Wounds, Paving Path To Pivotal Trial
VT-1953 treatment over 14 days resulted in highly statistically significant improvements in bad smell or malodor associated with malignant fungating wound (primary endpoint) (P =…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
1 year ago benzinga.com
Vyome Acquires Oculo, An AI Startup Launched At The Massachusetts Institute Of Technology And Launched A New Business Unit Focused On Using AI To Tackle Inflammation; Deal Terms Were Undisclosed
This new business unit will leverage Oculo's assets to develop an AI psychiatrist trained on data from both the US and India, and will be overseen by a newly-formed Vyome Board of Directors AI…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
1 year ago benzinga.com
Market-Moving News for September 17th
SPRC: 268% | SciSparc shares are trading higher after Automax Motors filed a motion to Jerusalem District Court in connection with its merger with the company. HIND: 199% | Vyome Unveils Preclinical…
-
1 year ago benzinga.com
Vyome Unveils Preclinical Data For VT-1908 Eye Drops To Treat Uveitis, A Leading Cause Of Blindness
Vyome Holdings, Inc. (NASDAQ:HIND), a clinical-stage healthcare holding company, presented results from its preclinical studies investigating VT-1908 (the first topical formulation of mycophenolate)…
1 year ago benzinga.com
Deal Dispatch: Musk-Altman Drama, Ashton Kutcher SoHo House Play And We Pose Questions To Private Equity Pros
Elon's OpenAI bid flops, Vyome reviews Livechain, Peraso courts acquirers, GTCR faces antitrust and pizza chains go bankrupt.
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
1 year ago benzinga.com
Empery Digital, Riskified And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Empery Digital, Riskified And Other Big Stocks Moving Lower In Monday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session